Analysts think IPSC stock price could increase by 972%
Apr 14, 2025, 11:25 AM
7.82%
What does IPSC do
Century Therapeutics, based in Philadelphia, develops off-the-shelf allogeneic cell therapies for cancer, employing 152 staff since its IPO on June 17, 2021. Its product candidates target various malignancies, including CNTY-101 and CNTY-102 for B-cell lymphoma.
7 analysts think IPSC stock price will increase by 971.65%. The current median analyst target is $5.10 compared to a current stock price of $0.48. The lowest analysts target is $2.02 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.